Journey Medical reports record FY22 revenue of $73.7M (+17% YoY); net loss narrows to $29.6M

Journey Medical Corp

Record total revenues of $73.7M for FY2022, up 17% from $63.1M in FY2021.
Net loss of $29.6M ($1.69/share) vs $44.0M ($4.32/share) in prior year; Adjusted EBITDA -$7.3M.
Phase 3 DFD-29 (rosacea) fully enrolled; topline data expected H1 2023; NDA filing H2 2023.
Q4 2022 revenue $16.0M, down 9% YoY due to Targadox generic competition.
SG&A expenses rose to $59.5M from $39.8M; R&D decreased to $10.9M from $16.6M.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Journey Medical Corp reported fourth quarter and full year ended December 31, 2022 results: revenue Total revenues were $73.7 million for the full year 2022, net income Net loss was $29.6 million, or $1.69 per share basic and diluted, for the full year 2022, EPS $1.69 per share basic and diluted.

Period: fourth quarter and full year ended December 31, 2022
Revenue: Total revenues were $73.7 million for the full year 2022
Net income: Net loss was $29.6 million, or $1.69 per share basic and diluted, for the full year 2022
EPS: $1.69 per share basic and diluted
Result: reported results

Exact text from the filing

Total revenues were $73.7 million for the full year 2022, a record high for the Company, compared to total revenues of $63.1 million for the full year 2021, representing 17% growth.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Journey Medical Corp reported fourth quarter ended December 31, 2022 results: revenue total revenues of $16.0 million for the fourth quarter of 2022, net income Net loss was $10.6 million, or $0.60 per share basic and diluted, for the fourth quarter of 2022, EPS $0.60 per share basic and diluted.

Period: fourth quarter ended December 31, 2022
Revenue: total revenues of $16.0 million for the fourth quarter of 2022
Net income: Net loss was $10.6 million, or $0.60 per share basic and diluted, for the fourth quarter of 2022
EPS: $0.60 per share basic and diluted
Result: reported results

Exact text from the filing

This includes total revenues of $16.0 million for the fourth quarter of 2022, compared to net revenues of $17.5 million generated in the fourth quarter of 2021, representing a 9% decline from period-to-period primarily due to generic competition for Targadox.

View on SEC.gov

Browse all earnings releases →

Journey Medical Corp filing history →

Source: SEC EDGAR

accession 0001104659-23-038309

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.